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Almtract 
High-molecular-weight [t4C]hyaluronate was incubated with cultured fibroblasts from human uterine cervix and skin, and then the depolymeriza- 
tion of the hyaluronate was investigated. [14C]Hyaluronate in the medium of skin fibroblasts was depolymerized into a constant molecular weight 
(Mr about 40,000), whereas that of cervix fibroblasts was not depolymerized, irrespective of incubation period. However, when progesterone was 
added to the medium of cervix fibroblasts, hyaluronate was depolymerized to the same xtent as that in skin fibroblasts. The reducing terminal sugar 
of the depolymerized hyaluronate was N-aeetylglucosamine. These results uggest that a hyaluronate-depolymerizing enzyme, endo-,&N-acetylglu- 
cosaminidase, was induced by progesterone in cultured fibroblasts derived from human uterine cervix. 
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1. Introduction 
Hyaluronate is widely distributed in tissue as one of 
the major components of the extracellular matrix. Its 
catabolism seems to occur through cleavage of the inter- 
nal bonds of the sugar chain by hyaluronidase ( ndo-p- 
N-acetylhexosaminidase). The resulting oligosaccharides 
are then depolymerized successively by exo-fl-glucu- 
ronidase and exo-fl-N-acetylhexosaminidase from the 
nonreducing terminal [1], and at the final step, the result- 
ing disaccharide is completely depolymerized to mono- 
saccharide by disaccharide-depolymerizing exo-fl-glucu- 
ronidase [2]. 
With regard to the mechanism of hyaluronate de- 
polymerization i  skin, Arbogast et al. demonstrated an
absence of hyaluronidase in cultured human skin fibrob- 
lasts [3]. Nakamura et al. recently reported that high- 
molecular-weight yaluronate was depolymerized to a 
constant molecular weight (Mr = 40,000) in the culture 
medium, and that the reducing terminal of the depolym- 
erized molecule was a newly exposed N-acetylglucosam- 
ine [4]. Thus the presence of a hyaluronate-depolymer- 
izing enzyme, endo-fl-N-acetylglucosaminidase, was 
demonstrated in cultured human skin fibroblasts. Since 
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Abbreviations: Dex, dexamethasone; DHAS, dehydroepiandrosterone 
sulfate; PGFu, prostaglandin F,.; PGE2, prostaglandin E2; IL-1 ~t, inter- 
leukin lg; DMEM, Dulbecco's modified Eagle medium; CMF-PBS, 
Dulbeeco's calcium- and magnesium-free phosphate-buffered saline; 
FBS, fetal bovine serum; HPLC, high-performance liquid chromatog- 
raphy. 
then, hyaluronate-depolymerizing enzymes having a sim- 
ilar mechanism of action have been reported by other 
investigators [5,6]. 
In human uterine cervical connective tissue, it has been 
reported that the amount of hyaluronate increases mark- 
edly at the last stage of pregnancy and quickly decreases 
after parturition [7-9]. However, the mechanism respon- 
sible for the rapid depolymerization f hyaluronate after 
parturition in human uterine cervix has not yet been 
clarified. In order to resolve this issue, changes in the 
molecular weight of hyaluronate during fibroblast incu- 
bation and the effects of hormones on the hyaluronate 
depolymerization by cultured human uterine cervix fi- 
broblasts were investigated. It was found that hy- 
aluronate depolymerization activity corresponding to 
that reported by Nakamura et al. [4] was induced by 
progesterone in the cultured fibroblasts derived from 
human uterine cervix. 
2. Materials and methods 
2.1. Chemicals 
[14C]Hyaluronate (Mr = 1.86 x 106, specific activity 3.14/zCi/mg) and 
non-radioactive hyaluronate (Mr = 1.90 x 106, 1.0 × 105 and 4.0 x 104) 
were kindly supplied by Denki Kagaku Kogyo (Tokyo, Japan). 
[14C]Hyaluronate was synthesized by Streptococcus equi in medium 
containing i)-[U-14C]glucose. Sodium [3H]borohydride (specific activity 
100 Ci/mmol) was purchased from American Radiolabeled Chemicals 
(St. Louis, MO, USA). Dulbecco's modified Eagle medium (DMEM) 
and Dulbecco's calcium- and magnesium-free phosphate-buffered sa- 
line (CMF-PBS) were purchased from Nissui Pharmaceutical (Tokyo, 
Japan). Fetal bovine serum (FBS) and penicillin- streptomycin solution 
(penicillin 5,000 units/ml and streptomycin 5,000/~g/ml) were pur- 
chased from Gibco (Grand Island, NY, USA). Streptomyces hy- 
aluronidase was purchased from Seikagaku Kogyo (Tokyo, Japan). 
Dexamethasone (D x), dehydroepiandrosterone sulfate (DHAS), estra- 
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diol, progesterone, prostaglandin E2 (PGE2) and prostaglandin F~ 
(PGF~) were purchased from Sigma Chemical (St. Louis, MO, USA). 
Recombinant human interleukin-lct (IL-lct, specific activity, 1 x l0 s 
U/rag) was purchased from Genzyme (Boston, MA, USA). The progeS- 
terone antagonist RU38486 was kindly supplied by Roussel-Uclaf 
(Paris, France). Other eagents and chemicals were obtained from com- 
mercial sources. 
2.2. Cell culture 
A specimen of normal human uterine cervix was collected after a 
total hysterectomy foruterine myoma t Hirosaki University Hospital 
and Hirosaki City Hospital after informed consent had been obtained. 
Human skin was obtained from normal regions around a surgical 
wound at the time of scar removal. These tissue samples were cut into 
small pieces, which were then incubated inDMEM supplemented with 
FBS (10% v/v) and antibiotics at 37* in a humidified atmosphere of 5% 
CO2/95% air on 35-ram plastic dishes (Coming, Coming, NY, USA). 
After the fibroblasts had grown to conttuency, they were used at up to 
fifth passage for this study. 
2.3. Depolymerization f [U C]hyaluronate 
Human uterine cervix and skin fibroblasts at cortfluency were incu- 
bated in dishes containing medium supplemented with [~4C]hyaluronate 
(0.045/zCi, 14.3 pg/ml). After 5 h, 48 h and 120 h, the medium was 
recovered and each sample subjected directly to HPLC using a Shodex 
OHpak KB-805 column (0.8 × 30 cm, Showa Denko, Tokyo, Japan) 
eluted with 0.2 M NaC1 at 30 °. The flow rate was 1 ml/min, and 0.5-ml 
fractions were collected using a fraction collector. The radioactivity of
each fraction was measured by a liquid scintillation counter (LSC-3500, 
Aloka, Tokyo, Japan). Nun-radioactive hyaluronate (Mr = 1.90 x 106, 
1.0 x 105 and 4.0 × 104) and hyaluronate trasaccharides obtained by 
digestion with Streptomyces hyaluronidase were used as molecular 
weight standards. 
2.4. Effects of hormones and IL-lot on [UC]hyaluronate 
depolymerization 
The effects of hormones and IL-lct were investigated. First, cervix 
and skin fibroblasts were preincubated in medium containing hormones 
or IL-l~t. After preincubation for 12 h, the medium was removed and 
each cell layer was washed 3times with CMF-PBS. Then, incubation 
was continued with fresh medium containing [~4C]hyaluronate andthe 
same hormones or IL-lct. The medium was recovered after 5, 48, or 120 
h and subjected toHPLC. Hormones that are increased inthe plasma 
of pregnant women, and also IL-I~, were added to the medium in the 
form of an ethanol solution. The concentration f Dex, estradiol and 
progesterone (1 × 10 -7 M,  respectively) was based on the plasma con- 
centration i  pregnant women at term [10]. DHAS, PGE2 and PGF2= 
(1 x 10 -6 M, respectively) were used at theconcentration effective for 
ripening of the uterine cervix [11,12]. IL-l~t (1 ng/ml) was used at the 
concentration ptimal for effective synthesis of hyaluronate [13]. 
2.5. Identification of the reducing terminal sugar 
The reducing terminal sugar of the depolymerized hyal- uronate was 
investigated as described previously [14]. Cervix fibroblasts were prein- 
cubated in medium containing 10 -7 M progesterone. After preincuba- 
tion for 12 h, the medium was removed and incubation was continued 
with fresh medium containing non-radioactive hyaluronate (Mr = 1.90 
X 10 6, 1 mg/ml) and 10 -7 M progesterone, The medium was recovered 
after 120 h and the depolymerized hyaluronate (Mr about 40,000) was 
tritiated and reduced using NaB3H4, followed by acid hydrolysis. The 
product was subjected topaper chromatography, and the radioactivity 
on the paper was determined. 
3. Results 
3.1. Depolymerization o f  [14 C]hyaluronate in the 
incubation medium 
Human uterine cervix and skin fibroblasts were incu- 
bated in medium containing [~4C]hyaluronate for 5, 48 
and 120 h. After each incubat ion period, the medium was 
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Fig. 1. HPLC of [14C]hyaluronate in the incubation medium. Human 
skin (A) and uterine cervix (B) fibroblasts were incubated in medium 
containing [l*C]hyaluronate for 5 h (O), 48 h (e) and 120 h (zx). After 
incubation, the medium was subjected directly to HPLC (column~ Sho- 
dex OHpak KB-805). Arrows indicate the elution positions of standard 
hyaluronate (Mr = 1.90 x 106, 1.0 x 105, 4.0 x 104 and hyaluronate 
tetrasaccharide (0.SK)). 
recovered and subjected irectly to HPLC. The high- 
molecular-weight yaluronate in the medium of skin 
fibroblasts was found to be depolymerized asthe incuba- 
tion period was prolonged, and after 120 h, the molecu- 
lar weight of the main depolymerized hyaluronate was 
estimated to be about 40,000 by HPLC,  although the 
depolymerized hyaluronate showed a dispersed elution 
profile (Fig. 1A). On the other hand, in the medium of 
cervix fibroblasts, the high-molecular-weight hy- 
aluronate was not depolymerized at all (Fig. 1 B). 
3.2. Effects o f  hormones and 1L - l s  on [14C]hyaluronate 
depolymerization 
In cervix fibroblasts, the effects of hormones and IL- 
l s  were then investigated. First, cervix fibroblasts were 
preincubated in medium containing hormones or IL-1 s. 
After preincubation for 12 h, the medium was removed 
and incubat ion was continued with fresh medium con- 
taining [~4C]hyaluronate and the same hormones or IL- 
ls .  The medium was recovered after 5, 48, or 120 h and 
subjected to HPLC. When DHAS was added to the cul- 
ture medium, the high-molecular-weight hyahironate 
was not depolymerized, irrespective of the incubation 
period (Fig. 2A). The same results were observed after 
addit ion of other hormones and IL-1 s (data not shown). 
Only when progesterone was added was the high-molec- 
ular-weight hyaluronate depolymerized to low molecular 
weight (Mr about 40,000) (Fig. 2B). 
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Fig. 2. Effects of hormones on [14C]hyaluronate d polymerization in 
human uterine cervix fibroblasts. Cervix fibroblasts was incubated with 
[14C]hyaluronate nd hormones or IL-I~z for 5 h (0), 48 h (0) and 120 
h (A). After incubation, the medium was subjected irectly to HPLC. 
A, DHAS; B, progesterone. Arrows indicate the elution positions of 
molecular weight standards. 
3.3. Effects of progesterone on [14C]hyaluronate 
depolymerization 
The stimulatory effects of various concentrations of 
progesterone onhyaluronate d polymerization by cervix 
fibroblasts were then studied. After incubation with pro- 
gesterone for 120 h, the medium was subjected to HPLC. 
As shown in Fig. 3A, the hyaluronate depolymerization 
described above was marked when 10-6-10 -7 M proges- 
terone was present. However, when the concentration f 
progesterone was below 10 -9 M, no hyaluronate de- 
polymerization was observed. 
To investigate whether the depolymerization f hy- 
aluronate was indeed stimulated by progesterone, vari- 
ous concentrations of the progesterone antagonist 
RU38486 [15] were added to the medium containing 10- 
7 M progesterone. After 120 h, the medium was recov- 
ered and the depolymerization f hyaluronate was esti- 
mated by HPLC. RU38486 added to the medium at 
10-11 M with 10 -7 M progesterone did not inhibit de- 
polymerization. However, as the concentration of 
RU38486 increased, the depolymerization of hy- 
aluronate began to be inhibited, and was completely 
abolished at a concentration f 10 -5 M (Fig. 3B). 
On the other hand, when some hormones (Dex, 
DHAS, estradiol, PGE2, PGF2~ and progesterone) and 
IL-hz were added to the culture medium of the skin 
fibroblasts, the molecular weight of the depolymerized 
products remained at about 40,000, and when 10 -7 M 
RU38486 was added to the medium, hyaluronate de- 
polymerization was not inhibited (data not shown). 
3. 4. Identification of the reducing terminal sugar 
The reducing terminal sugar of the hyaluronate which 
had been depolymerized byaddition of 10 -7 M proges- 
terone was then investigated by paper chromatography 
after reduction of the non-radioactive hyaluronate with 
NaB3H4 . The reducing terminal sugar was identified as 
N-acetylglucosamine (data not shown). 
4. Discussion 
Hyaluronate is one of the primary constituents of the 
extracellular matrix of the human uterine cervix, and it 
has been reported that the mount  of hyaluronate in- 
creases to about 10 times the regular level at the onset 
of labor and decreases quickly to the former level after 
parturition [7,9]. This dramatic hange appears to indi- 
cate that hyaluronate plays an important role in the reg- 
ulation of uterine cervical function during parturition. 
However, the mechanisms ofhyaluronate d polymeriza- 
tion and its regulation in the uterine cervix are not yet 
clear. 
In the present study, in order to elucidate the mecha- 
nism of hyaluronate depolymerization in cervix fibro- 
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Fig. 3. Effects of progesterone on [z4C]hyaluronate d polymerization 
in human uterine cervix fibroblasts. (A) [14C]HyaJuronate depolymeri- 
zation in human cervix fibroblasts was studied using various concentra- 
tions of progesterone. ©, 10 -6 M; o, 10 -7 M; A, 10 -9 M. (B) Various 
concentrations of progesterone antagonist, RU38486, were added to 
the medium along with 10 -7 M progesterone, o, 10 -7 M progesterone 
(control); o, 10 -5 M RU38486 with 10 -7 M progesterone; A, 10 -9 M 
RU38486 with 10 -7 M progesterone; Iq,10-" M RU38486 with 10 -7 M 
progesterone. Arrows indicate the elution positions of molecular weight 
standards. 
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blasts, the activity of hyaluronidase was measured by the 
method of Nakamura et al. using fluorogenic hy- 
aluronate as a substrate [16]. Hyaluronidase degrades 
hyaluronate into oligosaccharides (tetra- and hexasac- 
charides). However, it was found that ofigosaccharides 
such as tetra- and hexasaccharides were undetectable in 
both the conditioned medium and the cell layer (data not 
shown). Therefore, the depolymerization f radioactive 
[14C]hyaluronate was investigated in medium derived 
from cervix and skin fibroblasts. It was found that the 
hyaluronate of high molecular weight in the medium of 
skin fibroblasts was depolymerized to units of Mr about 
40,000, corresponding to the previous report of 
Nakamura et al. [4] (Fig. 1A). 
In cervix fibroblasts, only when progesterone was 
added to the medium was hyaluronate depolymerization 
observed, and the Mr of the main depolymerization 
product was estimated tobe about 40,000 by HPLC (Fig. 
2B). However, prolongation of the incubation time did 
not produce oligosaccharides, as shown by hy- 
aluronidase digestion. Furthermore, the progesterone 
antagonist RU38486 effectively inhibited the progester- 
one-induced depolymerization f hyaluronate in a dose- 
dependent manner, as shown in Fig. 3B. These results 
suggest that the depolymerization f hyaluronate is in- 
duced by progesterone and may be regulated through the 
progesterone receptor. Furthermore, the reducing termi- 
nal sugar of the depolymerized hyaluronate was identi- 
fied as N-acetylglucosamine. Therefore, it seems that 
progesterone binds to progesterone r ceptors in cervix 
fibroblasts and induces a novel endo-fl-N-acetylglu- 
cosaminidase, which is different from the hyaluronidase. 
The mechanism responsible for this induction is still not 
clear, but the enzyme may be similar to the endo-fl-N- 
acetylglucosaminidase reported by Nakamura et al. [4]. 
It is likely that further study of the depolymerizing en- 
zyme induced by progesterone will help to elucidate the 
mechanisms of hyaluronate depolymerization a d its 
regulation i  the connective tissue of the human uterine 
cervix after parturition. 
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